Posttranslational Modification in Bone Homeostasis and Osteoporosis

Abstract

Bone is responsible for providing mechanical protection, attachment sites for muscles, hematopoiesis micssroenvironment, and maintaining balance between calcium and phosphorate. As a highly active and dynamically regulated organ, the balance between formation and resorption of bone is crucial in bone development, damaged bone repair, and mineral homeostasis, while dysregulation in bone remodeling impairs bone structure and strength, leading to deficiency in bone function and skeletal disorder, such as osteoporosis. Osteoporosis refers to compromised bone mass and higher susceptibility of fracture, resulting from several risk factors deteriorating the balanced system between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. This balanced system is strictly regulated by translational modification, such as phosphorylation, methylation, acetylation, ubiquitination, sumoylation, glycosylation, ADP-ribosylation, S-palmitoylation, citrullination, and so on. This review specifically describes the updating researches concerning bone formation and bone resorption mediated by posttranslational modification. We highlight dysregulated posttranslational modification in osteoblast and osteoclast differentiation. We also emphasize involvement of posttranslational modification in osteoporosis development, so as to elucidate the underlying molecular basis of osteoporosis. Then, we point out translational potential of PTMs as therapeutic targets. This review will deepen our understanding between posttranslational modification and osteoporosis, and identify novel targets for clinical treatment and identify future directions.

Keywords

bone formation / bone resorption / osteoporosis / posttranslational modification

References

[1] R. Florencio-Silva, G. R. Sasso, E. Sasso-Cerri, M. J. Simões, and P. S. Cerri, “Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells,” BioMed Research International 2015 (2015): 421746.

[2] T. H. Ambrosi, M. T. Longaker, and C. K. F. Chan, “A Revised Perspective of Skeletal Stem Cell Biology,” Frontiers in Cell and Developmental Biology 7 (2019): 189.

[3] C. S. Soltanoff, S. Yang, W. Chen, and Y. P. Li, “Signaling Networks That Control the Lineage Commitment and Differentiation of Bone Cells,” Critical Reviews in Eukaryotic Gene Expression 19, no. 1 (2009): 1-46.

[4] X. Yang, K. Matsuda, P. Bialek, et al., “ATF4 is a Substrate of RSK2 and an Essential Regulator of Osteoblast Biology; Implication for Coffin-Lowry Syndrome,” Cell 117, no. 3 (2004): 387-398.

[5] A. Bozec, L. Bakiri, M. Jimenez, T. Schinke, M. Amling, and E. F. Wagner, “Fra-2/AP-1 Controls Bone Formation by Regulating Osteoblast Differentiation and Collagen Production,” Journal of Cell Biology 190, no. 6 (2010): 1093-1106.

[6] C. E. Jacome-Galarza, S. K. Lee, J. A. Lorenzo, and H. L. Aguila, “Identification, Characterization, and Isolation of a Common Progenitor for Osteoclasts, Macrophages, and Dendritic Cells From Murine Bone Marrow and Periphery,” Journal of Bone and Mineral Research 28, no. 5 (2013): 1203-1213.

[7] X. Chen, X. Zhu, A. Wei, et al., “Nrf2 epigenetic Derepression Induced by Running Exercise Protects Against Osteoporosis,” Bone Res 9, no. 1 (2021): 15.

[8] A. V. Zamaraev, G. S. Kopeina, E. A. Prokhorova, B. Zhivotovsky, and I. N. Lavrik, “Post-translational Modification of Caspases: The Other Side of Apoptosis Regulation,” Trends in Cell Biology 27, no. 5 (2017): 322-339.

[9] H. Wang, L. Yang, M. Liu, and J. Luo, “Protein Post-translational Modifications in the Regulation of Cancer Hallmarks,” Cancer Gene Therapy 30, no. 4 (2023): 529-547.

[10] G. A. Rodan, “Bone Homeostasis,” PNAS 95, no. 23 (1998): 13361-13362.

[11] L. Shen, G. Hu, and C. M. Karner, “Bioenergetic Metabolism in Osteoblast Differentiation,” Curr Osteoporos Rep 20, no. 1 (2022): 53-64.

[12] X. Zhong, F. Zhang, X. Yin, et al., “Bone Homeostasis and Gut Microbial-Dependent Signaling Pathways,” Journal of Microbiology and Biotechnology 31, no. 6 (2021): 765-774.

[13] M. Zhou and D. T. Graves, “Impact of the Host Response and Osteoblast Lineage Cells on Periodontal Disease,” Frontiers in Immunology 13 (2022): 998244.

[14] N. A. Sims and T. J. Martin, “Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells through Multiple Mechanisms,” Annual Review of Physiology 82 (2020): 507-529.

[15] J. Delgado-Calle and T. Bellido, “The Osteocyte as a Signaling Cell,” Physiological Reviews 102, no. 1 (2022): 379-410.

[16] A. G. Robling and L. F. Bonewald, “The Osteocyte: New Insights,” Annu Rev Physiol 82: 485-506 (2020).

[17] H. Kitaura, A. Marahleh, F. Ohori, et al., “Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption,” International Journal of Molecular Sciences 21, no. 14 (2020).

[18] L. Zhu, Y. Tang, X. Y. Li, et al., “Osteoclast-Mediated Bone Resorption is Controlled by a Compensatory Network of Secreted and Membrane-Tethered Metalloproteinases,” Science Translational Medicine 12, no. 529 (2020).

[19] D. J. Veis and C. A. O'Brien, “Osteoclasts, Master Sculptors of Bone,” Annu Rev Pathol 18 (2023): 257-281.

[20] S. H. Mun, P. S. U. Park, and K. H. Park-Min, “The M-CSF Receptor in Osteoclasts and Beyond,” Experimental & Molecular Medicine 52, no. 8 (2020): 1239-1254.

[21] A. Leibbrandt and J. M. Penninger, “RANKL/RANK as Key Factors for Osteoclast Development and Bone Loss in Arthropathies,” Advances in Experimental Medicine and Biology 649 (2009): 100-113.

[22] B. Adejuyigbe, J. Kallini, D. Chiou, and J. R. Kallini, “Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics,” International Journal of Molecular Sciences 24, no. 19 (2023).

[23] J. A. Siddiqui and N. C. Partridge, “Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement,” Physiology (Bethesda, Md.) 31, no. 3 (2016): 233-245.

[24] Y. Shen, X. Huang, J. Wu, et al., “The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990-2019,” Front Endocrinol (Lausanne) 13 (2022): 882241.

[25] A. Aibar-Almazán, A. Voltes-Martínez, Y. Castellote-Caballero, D. F. Afanador-Restrepo, M. D. C. Carcelén-Fraile, and E. López-Ruiz, “Current Status of the Diagnosis and Management of Osteoporosis,” International Journal of Molecular Sciences 23, no. 16 (2022).

[26] T. Sözen, L. Özışık, and N. Başaran, “An Overview and Management of Osteoporosis,” Eur J Rheumatol 4, no. 1 (2017): 46-56.

[27] A. Mizuno, T. Kanno, M. Hoshi, et al., “Transgenic Mice Overexpressing Soluble Osteoclast Differentiation Factor (sODF) Exhibit Severe Osteoporosis,” Journal of Bone and Mineral Metabolism 20, no. 6 (2002): 337-344.

[28] W. Chen, P. Wu, F. Yu, G. Luo, L. Qing, and J. Tang, “HIF-1α Regulates Bone Homeostasis and Angiogenesis, Participating in the Occurrence of Bone Metabolic Diseases,” Cells 11, no. 22 (2022): 3552.

[29] H. Gong, H. Zhong, L. Cheng, L. P. Li, and D. K. Zhang, “Post-translational Protein Lactylation Modification in Health and Diseases: A Double-edged Sword,” Journal of translational medicine 22, no. 1 (2024): 41.

[30] E. Q. Jennings, K. S. Fritz, and J. J. Galligan, “Biochemical Genesis of Enzymatic and Non-Enzymatic Post-translational Modifications,” Molecular Aspects of Medicine 86 (2022): 101053.

[31] S. Wang, A. O. Osgood, and A. Chatterjee, “Uncovering Post-translational Modification-Associated Protein-Protein Interactions,” Current Opinion in Structural Biology 74 (2022): 102352.

[32] G. Yao and Z. Yang, “Glypican-3 Knockdown Inhibits the Cell Growth, Stemness, and Glycolysis Development of Hepatocellular Carcinoma Cells Under Hypoxic Microenvironment Through Lactylation,” Archives of Physiology and Biochemistry 130, no. 5 (2024): 546-554.

[33] J. Wang, P. Yang, T. Yu, et al., “Lactylation of PKM2 Suppresses Inflammatory Metabolic Adaptation in Pro-inflammatory Macrophages,” Int J Biol Sci 18, no. 16 (2022): 6210-6225.

[34] H. Cui, N. Xie, S. Banerjee, et al., “Lung Myofibroblasts Promote Macrophage Profibrotic Activity Through Lactate-induced Histone Lactylation,” American Journal of Respiratory Cell and Molecular Biology 64, no. 1 (2021): 115-125.

[35] T. Bilbrough, E. Piemontese, and O. Seitz, “Dissecting the Role of Protein Phosphorylation: A Chemical Biology Toolbox,” Chem. Soc. Rev. 51, no. 13 (2022): 5691-5730.

[36] V. Singh, M. Ram, R. Kumar, R. Prasad, B. K. Roy, and K. K. Singh, “Phosphorylation: Implications in Cancer,” Protein Journal 36, no. 1 (2017): 1-6.

[37] M. Liu, G. Goldman, M. MacDougall, and S. Chen, “BMP Signaling Pathway in Dentin Development and Diseases,” Cells 11, no. 14 (2022).

[38] J. L. Wrana, L. Attisano, J. Cárcamo, et al., “TGF Beta Signals Through a Heteromeric Protein Kinase Receptor Complex,” Cell 71, no. 6 (1992): 1003-1014.

[39] B. Schmierer and C. S. Hill, “TGFbeta-SMAD Signal Transduction: Molecular Specificity and Functional Flexibility,” Nature Reviews Molecular Cell Biology 8, no. 12 (2007): 970-982.

[40] M. Wu, G. Chen, and Y. P. Li, “TGF-β and BMP Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease,” Bone Res 4 (2016): 16009.

[41] M. Inada, T. Yasui, S. Nomura, et al., “Maturational Disturbance of Chondrocytes in Cbfa1-Deficient Mice,” Developmental Dynamics 214, no. 4 (1999): 279-290.

[42] T. Takarada, E. Hinoi, R. Nakazato, et al., “An Analysis of Skeletal Development in Osteoblast-Specific and Chondrocyte-Specific Runt-Related Transcription Factor-2 (Runx2) Knockout Mice,” Journal of Bone and Mineral Research 28, no. 10 (2013): 2064-2069.

[43] A. C. Carreira, F. H. Lojudice, E. Halcsik, R. D. Navarro, M. C. Sogayar, and J. M. Granjeiro, “Bone Morphogenetic Proteins: Facts, Challenges, and Future Perspectives,” Journal of Dental Research 93, no. 4 (2014): 335-345.

[44] C. Nüsslein-Volhard and E. Wieschaus, “Mutations Affecting Segment Number and Polarity in Drosophila,” Nature 287, no. 5785 (1980): 795-801.

[45] R. Rohatgi, L. Milenkovic, and M. P. Scott, “Patched1 regulates Hedgehog Signaling at the Primary Cilium,” Science 317, no. 5836 (2007): 372-376.

[46] R. Tevlin, E. Y. Seo, O. Marecic, et al., “Pharmacological Rescue of Diabetic Skeletal Stem Cell Niches,” Science Translational Medicine 9, no. 372 (2017).

[47] C. Ma, H. Liu, Y. Wei, H. Li, D. Miao, and Y. Ren, “Exogenous PTH 1-34 Attenuates Impaired Fracture Healing in Endogenous PTH Deficiency Mice via Activating Indian Hedgehog Signaling Pathway and Accelerating Endochondral Ossification,” Frontiers in Cell and Developmental Biology 9 (2021): 750878.

[48] C. da C. J. Fernandes, A. S. do Nascimento, R. A. da Silva, and W. F. Zambuzzi, “Fibroblast Contributes for Osteoblastic Phenotype in a MAPK-ERK and Sonic Hedgehog Signaling-independent Manner,” Molecular and Cellular Biochemistry 436, no. 1-2 (2017): 111-117.

[49] R. Baron and M. Kneissel, “WNT Signaling in Bone Homeostasis and Disease: From human Mutations to Treatments,” Nature Medicine 19, no. 2 (2013): 179-192.

[50] S. Sangadala, C. H. Kim, L. M. Fernandes, et al., “Sclerostin Small-molecule Inhibitors Promote Osteogenesis by Activating Canonical Wnt and BMP Pathways,” Elife 12 (2023): e63402.

[51] K. Maeda, Y. Kobayashi, M. Koide, et al., “The Regulation of Bone Metabolism and Disorders by Wnt Signaling,” International Journal of Molecular Sciences 20, no. 22 (2019): 5525.

[52] M. N. Wein, Y. Liang, O. Goransson, et al., “SIKs Control Osteocyte Responses to Parathyroid Hormone,” Nature Communications 7 (2016): 13176.

[53] N. Su, X. Du, and L. Chen, “FGF Signaling: Its Role in Bone Development and Human Skeleton Diseases,” Frontiers in Bioscience 13 (2008): 2842-2865.

[54] J. Bhandari and P. K. Thada, Treasure Island (FL) Ineligible Companies. Disclosure: Pawan Thada Declares no Relevant Financial Relationships With Ineligible Companies.: StatPearls Publishing. (StatPearls Publishing LLC., 2024). Neural Tube Disorders. StatPearls. Copyright © 2024.

[55] D. M. Ornitz, “FGF Signaling in the Developing Endochondral Skeleton,” Cytokine & Growth Factor Reviews 16, no. 2 (2005): 205-213.

[56] M. Zhou, R. L. Sutliff, R. J. Paul, et al., “Fibroblast Growth Factor 2 Control of Vascular Tone,” Nature Medicine 4, no. 2 (1998): 201-207.

[57] M. Lewandoski, X. Sun, and G. R. Martin, “Fgf8 signalling From the AER Is Essential for Normal Limb Development,” Nature Genetics 26, no. 4 (2000): 460-463.

[58] Z. Lyu, H. Li, X. Li, et al., “Fibroblast Growth Factor 23 Inhibits Osteogenic Differentiation and Mineralization of Chicken Bone Marrow Mesenchymal Stem Cells,” Poultry Science 102, no. 1 (2023): 102287.

[59] L. C. Shuhaibar, J. W. Robinson, G. Vigone, et al., Dephosphorylation of the NPR2 Guanylyl Cyclase Contributes to Inhibition of Bone Growth by Fibroblast Growth Factor. Elife. 2017; 6:e31343.

[60] A. O. Wilkie, “Bad Bones, Absent Smell, Selfish Testes: The Pleiotropic Consequences of Human FGF Receptor Mutations,” Cytokine & Growth Factor Reviews 16, no. 2 (2005): 187-203.

[61] A. L. Jacob, C. Smith, J. Partanen, and D. M. Ornitz, “Fibroblast Growth Factor Receptor 1 Signaling in the Osteo-Chondrogenic Cell Lineage Regulates Sequential Steps of Osteoblast Maturation,” Developmental Biology 296, no. 2 (2006): 315-328.

[62] P. V. Hornbeck, J. M. Kornhauser, S. Tkachev, et al., “PhosphoSitePlus: A Comprehensive Resource for Investigating the Structure and Function of Experimentally Determined Post-translational Modifications in man and Mouse,” Nucleic Acids Res. 40 (2012): D261-270.

[63] Q. Wu, M. Schapira, C. H. Arrowsmith, and D. Barsyte-Lovejoy, “Protein Arginine Methylation: From Enigmatic Functions to Therapeutic Targeting,” Nat Rev Drug Discovery 20, no. 7 (2021): 509-530.

[64] E. M. Rowe, V. Xing, and K. K. Biggar, “Lysine Methylation: Implications in Neurodegenerative Disease,” Brain Research 1707 (2019): 164-171.

[65] G. S. Baldwin and P. R. Carnegie, “Specific Enzymic Methylation of an Arginine in the Experimental Allergic Encephalomyelitis Protein From human Myelin,” Science 171, no. 3971 (1971): 579-581.

[66] W. Dai, J. Zhang, S. Li, et al., “Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy,” Frontiers in immunology 13 (2022): 865964.

[67] L. Zhang, G. Jiao, Y. You, et al., “Arginine Methylation of PPP1CA by CARM1 Regulates Glucose Metabolism and Affects Osteogenic Differentiation and Osteoclastic Differentiation,” Clinical and translational medicine 13, no. 9 (2023): e1369.

[68] J. H. Choi, A. R. Jang, D. I. Kim, et al., “PRMT1 mediates RANKL-induced Osteoclastogenesis and Contributes to Bone Loss in Ovariectomized Mice,” Experimental & Molecular Medicine 50, no. 8 (2018): 1-15.

[69] M. Ding, E. Cho, Z. Chen, S. W. Park, and T. H. Lee, “(S)-2-(Cyclobutylamino)-N-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-Hydroxypropyl)Isonicotinamide Attenuates RANKL-Induced Osteoclast Differentiation by Inhibiting NF-κB Nuclear Translocation,” International Journal of Molecular Sciences 24, no. 5 (2023): 4327.

[70] L. Wang, N. Niu, L. Li, R. Shao, H. Ouyang, and W. Zou, “H3K36 Trimethylation Mediated by SETD2 Regulates the Fate of Bone Marrow Mesenchymal Stem Cells,” PLoS Biology 16, no. 11 (2018): e2006522.

[71] L. Hu, Z. Cheng, L. Wu, et al., “Histone Methyltransferase SETDB1 Promotes Osteogenic Differentiation in Osteoporosis by Activating OTX2-Mediated BMP-Smad and Wnt/β-Catenin Pathways,” Human Cell 36, no. 4 (2023): 1373-1388.

[72] P. Kang, Z. Wu, Y. Huang, Z. Luo, S. Huo, and Q. Chen, “Histone H3K9 Demethylase JMJD2B/KDM4B Promotes Osteogenic Differentiation of Bone Marrow-derived Mesenchymal Stem Cells by Regulating H3K9me2 on RUNX2,” PeerJ 10 (2022): e13862.

[73] X. Cao, W. He, K. Rong, et al., “DZNep Promotes Mouse Bone Defect Healing via Enhancing both Osteogenesis and Osteoclastogenesis,” Stem Cell Res Ther 12, no. 1 (2021): 605.

[74] Y. Zhao, X. Hao, Z. Li, et al., “Role of Chromatin Modulator Dpy30 in Osteoclast Differentiation and Function,” Bone 159 (2022): 116379.

[75] Q. Qi, Y. Wang, X. Wang, et al., “Histone Demethylase KDM4A Regulates Adipogenic and Osteogenic Differentiation via Epigenetic Regulation of C/EBPα and Canonical Wnt Signaling,” Cellular and Molecular Life Sciences 77, no. 12 (2020): 2407-2421.

[76] X. Yang, G. Wang, Y. Wang, et al., “Histone Demethylase KDM7A Reciprocally Regulates Adipogenic and Osteogenic Differentiation via Regulation of C/EBPα and Canonical Wnt Signalling,” Journal of Cellular and Molecular Medicine 23, no. 3 (2019): 2149-2162.

[77] Y. Xia, A. Ikedo, J. W. Lee, T. Iimura, K. Inoue, and Y. Imai, “Histone H3K27 Demethylase, Utx, Regulates Osteoblast-to-Osteocyte Differentiation,” Biochemical and Biophysical Research Communications 2022; 590: 132-138.

[78] R. Wang, H. Luo, D. Yang, et al., “Osteoblast Jmjd3 Regulates Osteoclastogenesis via EphB4 and RANKL Signalling,” Oral Diseases 29, no. 4 (2023): 1613-1621.

[79] H. Y. Sun, D. Yang, J. Mi, Y. Q. Yu, and L. H. Qiu, “Histone Demethylase Jmjd3 Modulates Osteoblast Apoptosis Induced by Tumor Necrosis Factor-alpha Through Directly Targeting RASSF5,” Connective Tissue Research 61, no. 6 (2020): 517-525.

[80] P. Rummukainen, K. Tarkkonen, A. Dudakovic, et al., “Lysine-Specific Demethylase 1 (LSD1) Epigenetically Controls Osteoblast Differentiation,” PLoS ONE 17, no. 3 (2022): e0265027.

[81] S. Gayatri and M. T. Bedford, “Readers of Histone Methylarginine Marks,” Biochimica Et Biophysica Acta 1839, no. 8 (2014): 702-710.

[82] K. A. Lawson, C. J. Teteak, J. Gao, et al., “ESET Histone Methyltransferase Regulates Osteoblastic Differentiation of Mesenchymal Stem Cells During Postnatal Bone Development,” Febs Letters 587, no. 24 (2013): 3961-3967.

[83] C. Zhao, N. Irie, Y. Takada, et al., “Bidirectional ephrinB2-EphB4 Signaling Controls Bone Homeostasis,” Cell metabolism 4, no. 2 (2006): 111-121.

[84] M. A. Gillette, S. Satpathy, S. Cao, et al., “Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma,” Cell 182, no. 1 (2020): 200-225. e235.

[85] B. J. Wilkins, N. A. Rall, Y. Ostwal, et al., “A Cascade of Histone Modifications Induces Chromatin Condensation in Mitosis,” Science 343, no. 6166 (2014): 77-80.

[86] M. Wang and H. Lin, “Understanding the Function of Mammalian Sirtuins and Protein Lysine Acylation,” Annual Review of Biochemistry 90 (2021): 245-285.

[87] C. Wang, R. Chen, X. Zhu, X. Zhang, and N. Lian, “DOT1L Decelerates the Development of Osteoporosis by Inhibiting SRSF1 Transcriptional Activity via microRNA-181-mediated KAT2B Inhibition,” Genomics 116, no. 1 (2024): 110759.

[88] J. Chen, D. Liu, B. Chen, et al., “The Histone Acetyltransferase Mof Regulates Runx2 and Osterix for Osteoblast Differentiation,” Cell and Tissue Research 393, no. 2 (2023): 265-279.

[89] M. Lee and N. C. Partridge, “Parathyroid Hormone Activation of Matrix Metalloproteinase-13 Transcription Requires the Histone Acetyltransferase Activity of p300 and PCAF and p300-Dependent Acetylation of PCAF,” Journal of Biological Chemistry 285, no. 49 (2010): 38014-38022.

[90] H. Jing, X. Su, B. Gao, et al., “Epigenetic Inhibition of Wnt Pathway Suppresses Osteogenic Differentiation of BMSCs During Osteoporosis,” Cell death & disease 9, no. 2 (2018): 176.

[91] D. Fei, Y. Wang, Q. Zhai, et al., “KAT6A Regulates Stemness of Aging Bone Marrow-Derived Mesenchymal Stem Cells Through Nrf2/ARE Signaling Pathway,” Stem Cell Res Ther 12, no. 1 (2021): 104.

[92] W. S. Lian, J. Y. Ko, Y. S. Chen, et al., “MicroRNA-29a Represses Osteoclast Formation and Protects Against Osteoporosis by Regulating PCAF-Mediated RANKL and CXCL12,” Cell death & disease 10, no. 10 (2019): 705.

[93] J. Wang, C. D. Wang, N. Zhang, et al., “Mechanical Stimulation Orchestrates the Osteogenic Differentiation of human Bone Marrow Stromal Cells by Regulating HDAC1,” Cell death & disease 7, no. 5 (2016): e2221.

[94] W. Zhang, L. Yu, F. Wang, M. Chen, and H. Li, “Rosavin Regulates Bone Homeostasis Through HDAC1-Induced Epigenetic Regulation of EEF2,” Chemico-Biological Interactions 384 (2023): 110696.

[95] C. J. Guo, J. J. Xie, R. H. Hong, H. S. Pan, F. G. Zhang, and Y. M. Liang, “Puerarin Alleviates Streptozotocin (STZ)-Induced Osteoporosis in Rats Through Suppressing Inflammation and Apoptosis via HDAC1/HDAC3 Signaling,” Biomedicine & Pharmacotherapy 115 (2019): 108570.

[96] C. Dou, N. Li, N. Ding, et al., “HDAC2 Regulates FoxO1 During RANKL-Induced Osteoclastogenesis,” American Journal of Physiology. Cell Physiology 310, no. 10 (2016): C780-787.

[97] L. R. Carpio, E. W. Bradley, M. E. McGee-Lawrence, et al., “Histone Deacetylase 3 Supports Endochondral Bone Formation by Controlling Cytokine Signaling and Matrix Remodeling,” Science signaling 9, no. 440 (2016): ra79.

[98] D. Zhang, J. Du, M. Yu, and L. Suo, “Urine-Derived Stem Cells-Extracellular Vesicles Ameliorate Diabetic Osteoporosis Through HDAC4/HIF-1α/VEGFA Axis by Delivering microRNA-26a-5p,” Cell Biology and Toxicology 39, no. 5 (2023): 2243-2257.

[99] J. Y. Ko, P. C. Chuang, H. J. Ke, Y. S. Chen, Y. C. Sun, and F. S. Wang, “MicroRNA-29a Mitigates Glucocorticoid Induction of Bone Loss and Fatty Marrow by Rescuing Runx2 Acetylation,” Bone 81 (2015): 80-88.

[100] Y. Shangguan, X. Li, J. Qin, Y. Wen, H. Wang, and L. Chen, “Positive Programming of the GC-IGF1 Axis Mediates Adult Osteoporosis Susceptibility in Male Offspring Rats Induced by Prenatal Dexamethasone Exposure,” Biochemical Pharmacology 206 (2022): 115264.

[101] J. S. Kang, T. Alliston, R. Delston, and R. Derynck, “Repression of Runx2 Function by TGF-beta Through Recruitment of Class II Histone Deacetylases by Smad3,” Embo Journal 24, no. 14 (2005): 2543-2555.

[102] J. Li, C. Liu, Y. Li, et al., “TMCO1-Mediated Ca(2+) Leak Underlies Osteoblast Functions via CaMKII Signaling,” Nature Communications 10, no. 1 (2019): 1589.

[103] C. Ma, J. Gao, J. Liang, et al., “HDAC6 Inactivates Runx2 Promoter to Block Osteogenesis of Bone Marrow Stromal Cells in Age-related Bone Loss of Mice,” Stem Cell Res Ther 12, no. 1 (2021): 484.

[104] Z. Jin, W. Wei, P. C. Dechow, and Y. Wan, “HDAC7 Inhibits Osteoclastogenesis by Reversing RANKL-Triggered β-catenin Switch,” Molecular Endocrinology 27, no. 2 (2013): 325-335.

[105] Y. Fu, P. Zhang, J. Ge, et al., “Histone Deacetylase 8 Suppresses Osteogenic Differentiation of Bone Marrow Stromal Cells by Inhibiting Histone H3K9 Acetylation and RUNX2 Activity,” International Journal of Biochemistry & Cell Biology 54 (2014): 68-77.

[106] B. Wang, S. Gong, L. Han, et al., “Knockdown of HDAC9 Inhibits Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Partially by Suppressing the MAPK Signaling Pathway,” CIA 17 (2022): 777-787.

[107] H. Xiao, Z. Wu, B. Li, et al., “The Low-expression Programming of 11β-HSD2 Mediates Osteoporosis Susceptibility Induced by Prenatal Caffeine Exposure in Male Offspring Rats,” British Journal of Pharmacology 177, no. 20 (2020): 4683-4700.

[108] S. Iyer, L. Han, S. M. Bartell, et al., “Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing β-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors,” Journal of Biological Chemistry 289, no. 35 (2014): 24069-24078.

[109] D. Zhou, Y. Ran, R. Yu, G. Liu, D. Ran, and Z. Liu, “SIRT1 Regulates Osteoblast Senescence Through SOD2 Acetylation and Mitochondrial Dysfunction in the Progression of Osteoporosis Caused by Cadmium Exposure,” Chemico-Biological Interactions 382 (2023): 110632.

[110] M. Fukuda, T. Yoshizawa, M. F. Karim, et al., “SIRT7 has a Critical Role in Bone Formation by Regulating Lysine Acylation of SP7/Osterix,” Nature Communications 9, no. 1 (2018): 2833.

[111] Y. Jing, Y. Zhou, F. Zhou, et al., “SIRT2 Deficiency Prevents Age-related Bone Loss in Rats by Inhibiting Osteoclastogenesis,” Cellular and Molecular Biology 65, no. 7 (2019): 66-71.

[112] W. Ling, K. Krager, K. K. Richardson, et al., “Mitochondrial Sirt3 Contributes to the Bone Loss Caused by Aging or Estrogen Deficiency,” JCI Insight 6, no. 10 (2021).

[113] L. Fang, G. Zhang, Y. Wu, Z. Li, S. Gao, and L. Zhou, “SIRT6 Prevents Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Rats,” Oxid Med Cell Longev 2022 (2022): 6360133.

[114] X. Shen, X. Chen, J. Huang, R. Xu, J. Cheng, and H. Jiang, “Age-Dependent Role of SIRT6 in Jawbone via Regulating Senescence and Autophagy of Bone Marrow Stromal Cells,” Journal of Molecular Histology 51, no. 1 (2020): 67-76.

[115] Y. J. Moon, Z. Zhang, I. H. Bang, et al., “Sirtuin 6 in Preosteoclasts Suppresses Age- and Estrogen Deficiency-Related Bone Loss by Stabilizing Estrogen Receptor α,” Cell Death and Differentiation 26, no. 11 (2019): 2358-2370.

[116] Y. Xu and W. Wan, “Acetylation in the Regulation of Autophagy,” Autophagy 19, no. 2 (2023): 379-387.

[117] Z. Wang, C. Zang, K. Cui, et al., “Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes,” Cell 138, no. 5 (2009): 1019-1031.

[118] M. Hu, L. Xing, L. Zhang, et al., “NAP1L2 drives Mesenchymal Stem Cell Senescence and Suppresses Osteogenic Differentiation,” Aging Cell 21, no. 2 (2022): e13551.

[119] W. Gu and R. G. Roeder, “Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-terminal Domain,” Cell 90, no. 4 (1997): 595-606.

[120] M. Shvedunova and A. Akhtar, “Modulation of Cellular Processes by Histone and Non-Histone Protein Acetylation,” Nature Reviews Molecular Cell Biology 23, no. 5 (2022): 329-349.

[121] Y. Wang, J. He, M. Liao, et al., “An Overview of Sirtuins as Potential Therapeutic Target: Structure, Function and Modulators,” European Journal of Medicinal Chemistry 161 (2019): 48-77.

[122] J. M. Marcus and S. A. Andrabi, “SIRT3 Regulation under Cellular Stress: Making Sense of the Ups and Downs,” Frontiers in neuroscience 12 (2018): 799.

[123] Y. Guo, X. Jia, Y. Cui, et al., “Sirt3-mediated Mitophagy Regulates AGEs-Induced BMSCs Senescence and Senile Osteoporosis,” Redox Biology 41 (2021): 101915.

[124] Q. Li, H. Wang, J. Zhang, et al., “Deletion of SIRT3 Inhibits Osteoclastogenesis and Alleviates Aging or Estrogen Deficiency-induced Bone Loss in Female Mice,” Bone 144 (2021): 115827.

[125] T. Sommer and D. H. Wolf, “The Ubiquitin-Proteasome-System,” Biochimica Et Biophysica Acta 1843, no. 1 (2014): 1.

[126] S. Toma-Fukai and T. Shimizu, “Structural Diversity of Ubiquitin E3 Ligase,” Molecules (Basel, Switzerland) 26, no. 21 (2021): 6682.

[127] J. A. Harrigan, X. Jacq, N. M. Martin, and S. P. Jackson, “Deubiquitylating Enzymes and Drug Discovery: Emerging Opportunities,” Nat Rev Drug Discovery 17, no. 1 (2018): 57-78.

[128] J. T. Hwang, A. Lee, and C. Kho, “Ubiquitin and Ubiquitin-Like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases,” International Journal of Molecular Sciences 23, no. 9 (2022).

[129] H. L. Zheng, W. N. Xu, W. S. Zhou, et al., “Beraprost Ameliorates Postmenopausal Osteoporosis by Regulating Nedd4-Induced Runx2 Ubiquitination,” Cell death & disease 12, no. 5 (2021): 497.

[130] W. Zhu, X. He, Y. Hua, Q. Li, J. Wang, and X. Gan, “The E3 Ubiquitin Ligase WWP2 Facilitates RUNX2 Protein Transactivation in a Mono-ubiquitination Manner During Osteogenic Differentiation,” Journal of Biological Chemistry 292, no. 27 (2017): 11178-11188.

[131] X. Huang, S. Jie, W. Li, and C. Liu, “GATA4-Activated lncRNA MALAT1 Promotes Osteogenic Differentiation Through Inhibiting NEDD4-Mediated RUNX1 Degradation,” Cell Death Discov 9, no. 1 (2023): 150.

[132] V. Upadhyay, A. K. Singh, S. Sharma, et al., “RING Finger E3 Ligase, RNF138 Inhibits Osteoblast Differentiation by Negatively Regulating Runx2 Protein Turnover,” Journal of Cellular Physiology 239, no. 5 (2024): e31217.

[133] G. Thacker, Y. Kumar, M. P. Khan, et al., “Skp2 Inhibits Osteogenesis by Promoting Ubiquitin-Proteasome Degradation of Runx2,” Biochimica Et Biophysica Acta 1863, no. 4 (2016): 510-519.

[134] H. Wang, Z. Liu, D. Niu, et al., “Carbamazepine Regulates USP10 Through miR-20a-5p to Affect the Deubiquitination of SKP2 and Inhibit Osteogenic Differentiation,” J Orthop Surg Res 18, no. 1 (2023): 820.

[135] K. Kaushal, A. Tyagi, J. K. Karapurkar, et al., “Genome-Wide CRISPR/Cas9-Based Screening for Deubiquitinase Subfamily Identifies Ubiquitin-Specific Protease 11 as a Novel Regulator of Osteogenic Differentiation,” International Journal of Molecular Sciences 23, no. 2 (2022): 856.

[136] Q. Zhu, Y. Fu, C. P. Cui, et al., “OTUB1 promotes Osteoblastic Bone Formation Through Stabilizing FGFR2,” Signal Transduct Target Ther 8, no. 1 (2023): 142.

[137] X. Lin, M. Liang, and X. H. Feng, “Smurf2 is a Ubiquitin E3 Ligase Mediating Proteasome-dependent Degradation of Smad2 in Transforming Growth Factor-beta Signaling,” Journal of Biological Chemistry 275, no. 47 (2000): 36818-36822.

[138] H. Zhu, P. Kavsak, S. Abdollah, J. L. Wrana, and G. H. Thomsen, “A SMAD Ubiquitin Ligase Targets the BMP Pathway and Affects Embryonic Pattern Formation,” Nature 400, no. 6745 (1999): 687-693.

[139] J. Kushioka, T. Kaito, R. Okada, et al., “A Novel Negative Regulatory Mechanism of Smurf2 in BMP/Smad Signaling in Bone,” Bone Res 8, no. 1 (2020): 41.

[140] J. Li, P. Wang, Z. Xie, et al., “TRAF4 positively Regulates the Osteogenic Differentiation of Mesenchymal Stem Cells by Acting as an E3 Ubiquitin Ligase to Degrade Smurf2,” Cell Death and Differentiation 26, no. 12 (2019): 2652-2666.

[141] X. Wang, C. Zou, C. Hou, et al., “Extracellular Vesicles From Bone Marrow Mesenchymal Stem Cells Alleviate Osteoporosis in Mice Through USP7-mediated YAP1 Protein Stability and the Wnt/β-catenin Pathway,” Biochemical Pharmacology 217 (2023): 115829.

[142] C. Li, M. Qiu, L. Chang, et al., “The Osteoprotective Role of USP26 in Coordinating Bone Formation and Resorption,” Cell Death and Differentiation 29, no. 6 (2022): 1123-1136.

[143] D. Baek, K. H. Park, K. M. Lee, et al., “Ubiquitin-specific Protease 53 Promotes Osteogenic Differentiation of human Bone Marrow-derived Mesenchymal Stem Cells,” Cell death & disease 12, no. 3 (2021): 238.

[144] Z. Xie, Y. Wu, Y. Shen, et al., “USP7 Inhibits Osteoclastogenesis via Dual Effects of Attenuating TRAF6/TAK1 Axis and Stimulating STING Signaling,” Aging Dis 14, no. 6 (2023): 2267-2283.

[145] Y. C. Lin, G. Zheng, H. T. Liu, et al., “USP7 promotes the Osteoclast Differentiation of CD14+ human Peripheral Blood Monocytes in Osteoporosis via HMGB1 Deubiquitination,” J Orthop Translat 40 (2023): 80-91.

[146] Z. Feng, S. Tao, Z. Huang, et al., “The Deubiquitinase UCHL1 Negatively Controls Osteoclastogenesis by Regulating TAZ/NFATC1 Signalling,” Int J Biol Sci 19, no. 8 (2023): 2319-2332.

[147] Z. G. Zheng, H. M. Cheng, Y. P. Zhou, et al., “Dual Targeting of SREBP2 and ERRα by Carnosic Acid Suppresses RANKL-mediated Osteoclastogenesis and Prevents Ovariectomy-induced Bone Loss,” Cell Death and Differentiation 27, no. 7 (2020): 2048-2065.

[148] X. Sun, B. Zhang, X. Pan, et al., “Octyl Itaconate Inhibits Osteoclastogenesis by Suppressing Hrd1 and Activating Nrf2 Signaling,” Faseb Journal 33, no. 11 (2019): 12929-12940.

[149] N. Rohatgi, W. Zou, Y. Li, et al., “BAP1 promotes Osteoclast Function by Metabolic Reprogramming,” Nature Communications 14, no. 1 (2023): 5923.

[150] S. Wang, Z. Deng, Y. Ma, et al., “The Role of Autophagy and Mitophagy in Bone Metabolic Disorders,” Int J Biol Sci 16, no. 14 (2020): 2675-2691.

[151] A. M. Pickrell and R. J. Youle, “The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease,” Neuron 85, no. 2 (2015): 257-273.

[152] D. Sun, Y. Peng, S. Ge, and Q. Fu, “USP1 Inhibits NF-κB/NLRP3 Induced Pyroptosis Through TRAF6 in Osteoblastic MC3T3-E1 Cells,” Journal of Musculoskeletal & Neuronal Interactions 22, no. 4 (2022): 536-545.

[153] Y. Liu, G. Cai, P. Chen, T. Jiang, and Z. Xia, “UBE2E3 regulates Cellular Senescence and Osteogenic Differentiation of BMSCs During Aging,” PeerJ 9 (2021): e12253.

[154] Y. Wei, J. Fu, W. Wu, P. Ma, L. Ren, and J. Wu, “Estrogen Prevents Cellular Senescence and Bone Loss Through Usp10-dependent p53 Degradation in Osteocytes and Osteoblasts: The Role of Estrogen in Bone Cell Senescence,” Cell and Tissue Research 386, no. 2 (2021): 297-308.

[155] P. Zhou, D. Xia, Y. Wang, et al., “Matrine Derivate MASM Protects Murine MC3T3-E1 Osteoblastic Cells Against Dexamethasone-induced Apoptosis via the Regulation of USP14/p53,” Artif Cells Nanomed Biotechnol 47, no. 1 (2019): 3720-3728.

[156] Y. Yang, Y. He, X. Wang, et al., “Protein SUMOylation Modification and Its Associations With Disease,” Open Biol 7, no. 10 (2017): 170167.

[157] J. M. Desterro, M. S. Rodriguez, G. D. Kemp, and R. T. Hay, “Identification of the Enzyme Required for Activation of the Small Ubiquitin-Like Protein SUMO-1,” Journal of Biological Chemistry 274, no. 15 (1999): 10618-10624.

[158] M. H. Tatham, S. Kim, E. Jaffray, J. Song, Y. Chen, and R. T. Hay, “Unique Binding Interactions Among Ubc9, SUMO and RanBP2 Reveal a Mechanism for SUMO Paralog Selection,” Nature structural & molecular biology 12, no. 1 (2005): 67-74.

[159] C. M. Hickey, N. R. Wilson, and M. Hochstrasser, “Function and Regulation of SUMO Proteases,” Nature Reviews Molecular Cell Biology 13, no. 12 (2012): 755-766.

[160] Z. Sheng, J. Zhu, Y. N. Deng, S. Gao, and S. Liang, “SUMOylation Modification-mediated Cell Death,” Open Biol 11, no. 7 (2021): 210050.

[161] Z. J. Han, Y. H. Feng, B. H. Gu, Y. M. Li, and H. Chen, “The Post-translational Modification, SUMOylation, and Cancer (Review),” International Journal of Oncology 52, no. 4 (2018): 1081-1094.

[162] Y. Zhang, Y. Chen, H. Sun, et al., “SENP3-Mediated PPARγ2 DeSUMOylation in BM-MSCs Potentiates Glucocorticoid-Induced Osteoporosis by Promoting Adipogenesis and Weakening Osteogenesis,” Frontiers in Cell and Developmental Biology 9 (2021): 693079.

[163] Y. Zhang, K. Yang, J. Yang, et al., “SENP3 Suppresses Osteoclastogenesis by De-conjugating SUMO2/3 From IRF8 in Bone Marrow-Derived Monocytes,” Cell reports 2020; 30(6): 1951-1963.e1954.

[164] C. Wang, X. Zhu, R. Chen, X. Zhang, and N. Lian, “Overexpression of SENP3 Promotes PPAR-γ Transcription Through the Increase of HIF-1α Stability via SUMO2/3 and Participates in Molecular Mechanisms of Osteoporosis,” Molecular and Cellular Endocrinology 577 (2023): 112014.

[165] D. Xiu, Z. Wang, L. Cui, J. Jiang, H. Yang, and G. Liu, “Sumoylation of SMAD 4 Ameliorates the Oxidative Stress-induced Apoptosis in Osteoblasts,” Cytokine 102 (2018): 173-180.

[166] A. Nayak, S. Viale-Bouroncle, C. Morsczeck, and S. Muller, “The SUMO-specific Isopeptidase SENP3 Regulates MLL1/MLL2 Methyltransferase Complexes and Controls Osteogenic Differentiation,” Molecular Cell 55, no. 1 (2014): 47-58.

[167] D. R. Rux, J. Y. Song, I. T. Swinehart, et al., “Regionally Restricted Hox Function in Adult Bone Marrow Multipotent Mesenchymal Stem/Stromal Cells,” Developmental Cell 39, no. 6 (2016): 653-666.

[168] J. Eichler, “Protein Glycosylation,” Current Biology 29, no. 7 (2019): R229-r231.

[169] A. Varki, “Biological Roles of Glycans,” Glycobiology 27, no. 1 (2017): 3-49.

[170] M. R. McClung, “Sclerostin Antibodies in Osteoporosis: Latest Evidence and Therapeutic Potential,” Ther Adv Musculoskelet Dis 9, no. 10 (2017): 263-270.

[171] S. Movérare-Skrtic, J. Voelkl, K. H. Nilsson, et al., “B4GALNT3 regulates Glycosylation of Sclerostin and Bone Mass,” EBioMedicine 91 (2023): 104546.

[172] S. Yang, Z. He, T. Wu, S. Wang, and H. Dai, “Glycobiology in Osteoclast Differentiation and Function,” Bone Res 11, no. 1 (2023): 55.

[173] C. L. Bartlett, M. G. Ralefatane, E. M. Cave, N. J. Crowther, and W. F. Ferris, “Differential Glycosylation of Tissue Non-specific Alkaline Phosphatase in Mesenchymal Stromal Cells Differentiated Into either an Osteoblastic or Adipocytic Phenotype,” Experimental Cell Research 421, no. 1 (2022): 113372.

[174] M. Dong, Q. Sun, X. Yu, et al., “OPN N-glycosylation Promoted Bone Destruction,” Oral Diseases 29, no. 5 (2023): 2154-2162.

[175] M. Cai, J. Li, R. Yue, Z. Wang, and Y. Sun, “Glycosylation of DMP1 Maintains Cranial Sutures in Mice,” Journal of Oral Rehabilitation 47 (2020): 19-28. Suppl 1.

[176] K. Makris, C. Mousa, and E. Cavalier, “Alkaline Phosphatases: Biochemistry, Functions, and Measurement,” Calcified Tissue International 112, no. 2 (2023): 233-242.

[177] Z. Zhang, H. K. Nam, S. Crouch, and N. E. Hatch, “Tissue Nonspecific Alkaline Phosphatase Function in Bone and Muscle Progenitor Cells: Control of Mitochondrial Respiration and ATP Production,” International Journal of Molecular Sciences 22, no. 3 (2021): 1140.

[178] W. Luo and L. Sun, “O-Linked N-Acetylglucosamine Transferase Regulates Bone Homeostasis through Alkaline Phosphatase Pathway in Diabetic Periodontitis,” Molecular Biotechnology (2023).

[179] M. Cai, Y. Chen, Y. Lin, et al., “SIRT1 Asn346 sugar Chain Promoting Collagen Deacetylation Protective Effect on Osteoblasts Under Stress,” Biochemical and Biophysical Research Communications 2023; 682: 148-155.

[180] L. Palazzo, P. Mikolčević, A. Mikoč, and I. Ahel, “ADP-ribosylation Signalling and human Disease,” Open Biol 9, no. 4 (2019): 190041.

[181] Y. Sasaki, R. Nakatsuka, T. Inouchi, M. Masutani, and T. Nozaki, “Inhibition of Poly (ADP-Ribose) Glycohydrolase Accelerates Osteoblast Differentiation in Preosteoblastic MC3T3-E1 Cells,” International Journal of Molecular Sciences 23, no. 9 (2022): 5041.

[182] C. Wang, J. Xiao, K. Nowak, et al., “PARP1 Hinders Histone H2B Occupancy at the NFATc1 Promoter to Restrain Osteoclast Differentiation,” Journal of Bone and Mineral Research 35, no. 4 (2020): 776-788.

[183] A. Robaszkiewicz, C. Qu, E. Wisnik, et al., “ARTD1 regulates Osteoclastogenesis and Bone Homeostasis by Dampening NF-κB-dependent Transcription of IL-1β,” Scientific Reports 6 (2016): 21131.

[184] T. Mukai, S. Fujita, and Y. Morita, “Tankyrase (PARP5) Inhibition Induces Bone Loss Through Accumulation of Its Substrate SH3BP2,” Cells 8, no. 2 (2019): 195.

[185] M. E. Linder and R. J. Deschenes, “Palmitoylation: Policing Protein Stability and Traffic,” Nature Reviews Molecular Cell Biology 8, no. 1 (2007): 74-84.

[186] B. Zhou, Q. Hao, Y. Liang, and E. Kong, “Protein Palmitoylation in Cancer: Molecular Functions and Therapeutic Potential,” Mol Oncol 17, no. 1 (2023): 3-26.

[187] I. Kaur, V. Yarov-Yarovoy, L. M. Kirk, et al., “Activity-Dependent Palmitoylation Controls SynDIG1 Stability, Localization, and Function,” Journal of Neuroscience 36, no. 29 (2016): 7562-7568.

[188] W. F. Leong, T. Zhou, G. L. Lim, and B. Li, “Protein Palmitoylation Regulates Osteoblast Differentiation Through BMP-induced Osterix Expression,” PLoS ONE 4, no. 1 (2009): e4135.

[189] A. Al Saedi, D. E. Myers, N. Stupka, and G. Duque, “1,25(OH)(2)D(3) Ameliorates Palmitate-induced Lipotoxicity in human Primary Osteoblasts Leading to Improved Viability and Function,” Bone 141 (2020): 115672.

[190] L. Ma, L. Zhang, Z. Liao, et al., “Pharmacological Inhibition of Protein S-palmitoylation Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-induced Bone Loss,” J Orthop Translat 42 (2023): 1-14.

[191] I. W. Song, W. R. Li, L. Y. Chen, et al., “Palmitoyl Acyltransferase, Zdhhc13, Facilitates Bone Mass Acquisition by Regulating Postnatal Epiphyseal Development and Endochondral Ossification: A Mouse Model,” PLoS ONE 9, no. 3 (2014): e92194.

[192] E. Darrah, A. Rosen, J. T. Giles, and F. Andrade, “Peptidylarginine Deiminase 2, 3 and 4 Have Distinct Specificities Against Cellular Substrates: Novel Insights Into Autoantigen Selection in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 71, no. 1 (2012): 92-98.

[193] H. J. Kim, H. R. Shin, H. Yoon, et al., “Peptidylarginine Deiminase 2 Plays a Key Role in Osteogenesis by Enhancing RUNX2 Stability Through Citrullination,” Cell death & disease 14, no. 8 (2023): 576.

[194] Y. H. Jin, E. J. Jeon, Q. L. Li, et al., “Transforming Growth Factor-beta Stimulates p300-dependent RUNX3 Acetylation, Which Inhibits Ubiquitination-mediated Degradation,” Journal of Biological Chemistry 279, no. 28 (2004): 29409-29417.

[195] X. Sun, Z. Xie, B. Hu, et al., “The Nrf2 Activator RTA-408 Attenuates Osteoclastogenesis by Inhibiting STING Dependent NF-κb Signaling,” Redox Biology 28 (2020): 101309.

[196] S. A. Z. Abidin, I. Othman, and R. Naidu, “Shotgun Proteomics and Mass Spectrometry as a Tool for Protein Identification and Profiling of Bio-Carrier-Based Therapeutics on Human Cancer Cells,” Methods in Molecular Biology 2211 (2021): 233-240.

[197] Y. Feng, R. Maity, J. P. Whitelegge, et al., “Mammalian Protein Arginine Methyltransferase 7 (PRMT7) Specifically Targets RXR Sites in Lysine- and Arginine-rich Regions,” Journal of Biological Chemistry 288, no. 52 (2013): 37010-37025.

[198] B. Emenike, O. Nwajiobi, and M. Raj, “Covalent Chemical Tools for Profiling Post-Translational Modifications,” Front Chem 10 (2022): 868773.

[199] D. M. Ray, E. Q. Jennings, I. Maksimovic, et al., “Chemical Labeling and Enrichment of Histone Glyoxal Adducts,” Acs Chemical Biology 17, no. 4 (2022): 756-761.

[200] N. Zhang, J. Wu, F. Hossain, et al., “Bioorthogonal Labeling and Enrichment of Histone Monoaminylation Reveal Its Accumulation and Regulatory Function in Cancer Cell Chromatin,” Journal of the American Chemical Society 2024 (2024).

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.